• PML has also been reported in patients receiving immune therapy with monoclonal antibodies (eg, natalizumab, rituximab) and various other immunosuppressants, including prednisone, cyclophosphamide, methotrexate, and cyclosporine. (medscape.com)
  • I. To evaluate whether the addition of vincristine/irinotecan to cyclophosphamide/ carboplatin/etoposide alternating with vincristine/doxorubicin/cyclophosphamide improves the event-free survival (EFS) of patients with newly diagnosed stage 4 diffuse anaplastic Wilms tumor (DAWT) as compared to historical controls. (clinicaltrials.gov)
  • To evaluate whether the addition of vincristine/irinotecan to cyclophosphamide/carboplatin/etoposide alternating with vincristine/doxorubicin/cyclophosphamide improves the EFS of patients with standard-risk relapsed favorable histology Wilms tumor (SRrFHWT) as compared to historical controls. (clinicaltrials.gov)
  • I. To evaluate whether the addition of vincristine/irinotecan to cyclophosphamide/carboplatin/etoposide alternating with vincristine/doxorubicin/cyclophosphamide improves the overall survival (OS) of patients with newly diagnosed stage 4 DAWT as compared to historical controls. (clinicaltrials.gov)
  • To establish EFS and OS for high-risk (HRrFHWT) and very high risk (VHRrFHWT) relapsed favorable histology Wilms tumor treated with ifosfamide/carboplatin/etoposide alternating with cyclophosphamide/ topotecan. (clinicaltrials.gov)
  • The patient arm of Ewing sarcoma patients receiving seclidemstat with chemotherapy drugs topotecan and cyclophosphamide (TC) advanced to the second lead-in safety cohort of patients receiving seclidemstat at 900 mg BID in combination with the two chemo drugs. (biospace.com)
  • Since you already used Platinum drugs twice (Carboplatin & Cisplatin), Taxol (Taxotere), Avastin (Bevacizumab), Doxil (DHL / PLD) and Topotecan (Hycamtin) - it leaves Gemzar (Gemcitabine) and Cyclophosphamide (Cytoxan / Neosar / Clafen). (cancer.org)
  • All patients received multi-agent induction chemotherapy for 6 cycles, including an initial 2 cycles of high-dose cyclophosphamide plus topotecan followed by blood stem cell collection. (oncologynurseadvisor.com)
  • After completion of induction chemotherapy, patients were randomly assigned to receive a single autologous HCT with CEM (carboplatin, etoposide, melphalan) chemotherapy or a double/tandem autologous HCT with thiotepa plus cyclophosphamide prior to the first transplantation followed by a modified CEM regimen prior to the second. (oncologynurseadvisor.com)
  • She also noted that it is now unclear which is the best consolidation regimen for this patient population, as randomized studies have evaluated different combinations of busulfan, melphalan, thiotepa, cyclophosphamide, and other chemotherapy agents. (oncologynurseadvisor.com)
  • Topotecan, sold under the brand name Hycamtin among others, is a chemotherapeutic agent medication that is a topoisomerase inhibitor. (wikipedia.org)
  • HYCAMTIN (topotecan) for injection, for intravenous use is supplied as a sterile, lyophilized, buffered, light yellow to greenish powder available in single-dose vials. (globalrph.com)
  • HYCAMTIN® for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. (globalrph.com)
  • HYCAMTIN for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. (globalrph.com)
  • HYCAMTIN for injection, in combination with cisplatin, is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment. (globalrph.com)
  • For HYCAMTIN for injection as a single agent, reduce the dose to 0.75 mg/m²/day for patients with creatinine clearance (CLcr) of 20 to 39 mL/min (calculated with the Cockcroft-Gault method using ideal body weight) [see CLINICAL PHARMACOLOGY ]. (globalrph.com)
  • SmithKline Beecham's Hycamtin for Recurrent Ovarian Cancer Recommended for Approval by FDA Committee BETHESDA, Md., April 19, 1996 -- The Oncologic Drugs Advisory Committee of the Food and Drug Administration today unanimously recommended approval of Hycamtin (topotecan hydrochloride) from SmithKline Beecham for the treatment of patients with metastatic ovarian cancer after failure of initial or subsequent chemotherapy. (bio.net)
  • In an open, randomized comparative study, patients treated with Hycamtin demonstrated a statistically significantly longer progression-free survival (time to progression) and a numerically superior response rate than patients treated with paclitaxel (Taxol). (bio.net)
  • Twenty-two patients enrolled in the study, of whom 20 were eligible and assessable for toxicity and 16 were assessable for response. (nih.gov)
  • I. To describe renal toxicity of ifosfamide/carboplatin/etoposide in HRrFHWT and VHRrFHWT patients using conventional and novel biomarkers of renal toxicity (urine NGAL, cystatin C and Kim1) in the context of the chemotherapy regimens used on this study. (clinicaltrials.gov)
  • Here, we have characterized the time- and concentration-dependent toxicity of topotecan in four human malignant glioma cell lines, LN-18, LN-229, LN-308 and T98G. (aspetjournals.org)
  • Neither short-term nor long-term topotecan toxicity was blocked by ectopic expression of bcl -2 or wild-type p53. (aspetjournals.org)
  • This combination regimen in patients with upper gastrointestinalmalignancies and breast cancer will be investigated as partof phase II studies, once the dose-limiting toxicity is determined. (cancernetwork.com)
  • APG-115-US-002 is an open-label, multi-center, Phase Ib/II study in U.S. , which was designed to assess safety, toxicity, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of APG-115 in combination with pembrolizumab in patients with advanced solid tumors. (pharmiweb.com)
  • Because pilot studies of tandem autologous HCT demonstrated tolerable toxicity and potential efficacy and because prior trials have demonstrated that dose intensification improves outcomes, researchers decided to explore tandem transplantation in patients with high-risk neuroblastoma. (oncologynurseadvisor.com)
  • However, the risk of toxicity is greater in this group than in patients with good performance status. (ersjournals.com)
  • Pembrolizumab is also indicated for unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mut/Mb] solid tumors in patients that have progressed following prior treatment and who have no alternative treatment options. (medscape.com)
  • The mission of the Brain Tumor Trials Collaborative (BTTC) is to develop and perform state-of-the-art clinical trials in a collaborative and collegial environment-advancing treatments for patients with brain and spine tumors that merge sound scientific methods with concern for patient well-being. (cancer.gov)
  • By collaborating with advocacy organizations and the BTTC network to perform clinical trials and care for patients, NCI-CONNECT aims to improve approaches to care and treatment for people with rare CNS tumors. (cancer.gov)
  • This clinical trial is investigating whether the immunotherapy drug nivolumab is an effective treatment for patients with rare CNS tumors. (cancer.gov)
  • This study examines tumor tissue from patients with rare CNS tumors and clinical data from patients who were pregnant at diagnosis or became pregnant after diagnosis to determine correlations with outcome. (cancer.gov)
  • UNC School of Medicine researchers have found for the first time a biochemical mechanism that could be a cause of "chemo brain" -- the neurological side effects such as memory loss, confusion, difficulty thinking, and trouble concentrating that many cancer patients experience while on chemotherapy to treat tumors in other parts of the body. (sciencedaily.com)
  • This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). (clinicaltrials.gov)
  • Topotecan is a novel topoisomerase I inhibitor that may have a role in the adjuvant chemotherapy of several solid tumors, including malignant glioma. (aspetjournals.org)
  • Samples of adrenal tumors were collected from patients undergoing adrenalectomy at the Department of Urology, the First Hospital of China Medical University. (cancerindex.org)
  • Phase I Study of Docetaxel and Topotecan in Patients with Solid Tumors. (umaryland.edu)
  • Phase III clinical trials of Rova‑T for patients with small‑cell lung cancer and a phase III clinical trial of nirogacestat for patients with desmoid tumors are ongoing. (spandidos-publications.com)
  • On the clinical side, I have developed expertise in the management of patients with neuroblastoma, germ cell tumors, and histiocytic diseases (such as Langerhans cell histiocytosis and hemophagocytic lymphohistiocytosis, or LCH and HLH). (chop.edu)
  • For patients with metastatic disease, cisplatin remains the most active agent. (medscape.com)
  • The combination of topotecan and cisplatin improves overall survival. (medscape.com)
  • RTOG 0417 was a development II study of 49 patients treated with bevacizumab in combination with concurrent radiotherapy and cisplatin in stage IIBВ-IIIB infirmity or IBВ-IIA disease with biopsy-proven pelvic nodal metastasis and/or tumor size of at least 5 cm [53]. (daubnet.com)
  • After the recurrence of disease on the paclitaxel, cisplatin, and bevacizumab regimen, the next option may be single-agent topotecan or bevacizumab, notes Michael J. Birrer, MD. In August 2014, the FDA approved bevacizumab in combination with paclitaxel plus cisplatin or topotecan as a treatment for women with persistent, recurrent, or metastatic cervical cancer. (onclive.com)
  • Purpose: A novel regimen designed to maximize anti-leukemia activity of carboplatin through inhibiting repair of platinum-DNA adducts was conducted in poor prognosis, acute leukemia patients. (ncl.ac.uk)
  • Experimental Design: Patients received fludarabine (10 to 15 mg/m2 × 5 days), carboplatin (area under the curve 10 to 12 by continuous infusion over 5 days), followed by escalated doses of topotecan infused over 72 hours (fludarabine, carboplatin, topotecan regimen). (ncl.ac.uk)
  • Maximum tolerated dose of fludarabine, carboplatin, topotecan regimen was fludarabine 15 mg/m2 × 5, carboplatin area under the curve 12, and topotecan 2.55 mg/m2 over 72 hours. (ncl.ac.uk)
  • Conclusions: Fludarabine, carboplatin, topotecan regimen is a promising treatment based on potential pharmacodynamic interactions, which merits additional study in poor prognosis, acute leukemia patients. (ncl.ac.uk)
  • Topotecan inhibits topoisomerase I restoring UBE3A levels to wild-type range in cultured mince neurons. (wikipedia.org)
  • Topotecan inhibits topoisomerase I, inhibiting DNA replication. (medscape.com)
  • This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT). (clinicaltrials.gov)
  • With the addition of granulocytecolony-stimulating factor (G-CSF [Neupogen]) to the regimen,patients received epirubicin at clinically relevant doses after dose-escalation.Results of the topoisomerase activity will be reported with thefinal results of this phase I study. (cancernetwork.com)
  • With the addition of granulocyte colony-stimulating factor (G-CSF [Neupogen]) to the regimen, patients received epirubicin at clinically relevant doses after dose-escalation. (cancernetwork.com)
  • This staging system was used to select the appropriate treatment regimen: chemotherapy in combination with thoracic radiotherapy in patients with LS-SCLC, and chemotherapy alone in patients with ES-SCLC. (ersjournals.com)
  • Patients received HER3-DXd 5.6 mg/kg intravenously once every 3 weeks or an uptitration regimen (3.2 â 4.8 â 6.4 mg/kg). (bvsalud.org)
  • We performed a phase 2 study in children with recurrent or refractory leptomeningeal leukemia to determine the objective response rate after treatment with intrathecal (IT) topotecan. (nih.gov)
  • Twenty-eight patients had acute myelogenous leukemia (7 untreated secondary acute myelogenous leukemia, 11 in first relapse, and 10 in second relapse or refractory), 1 patient had refractory/relapsed acute lymphoblastic leukemia, and 2 patients had untreated chronic myelogenous leukemia blast crisis. (ncl.ac.uk)
  • No. If the patient's health insurance plan denied coverage for Avastin (after submission of a Prior Authorization, if required), the patient can apply for help from the Genentech Patient Foundation. (avastin.com)
  • This phase 2 clinical study evaluated the effects and overall survival rates in newly diagnosed malignant glioma patients who received a combination of bevacizumab and erlotinib after completing radiation therapy with temozolomide. (cancer.gov)
  • This clinical study measured how well lacosamide prevented seizures in patients with malignant gliomas. (cancer.gov)
  • CD95 ligand (CD95L)-induced apoptosis was synergistically enhanced by short-term/high concentration but not long-term/low concentration exposure to topotecan, suggesting that topotecan sensitizes human malignant glioma cells to CD95L-induced apoptosis via inhibition of RNA synthesis. (aspetjournals.org)
  • Small cell lung cancer (SCLC) is an aggressive malignant disease, with the majority of patients presenting with distant metastasis at diagnosis. (ersjournals.com)
  • Topotecan injection is used to treat patients with metastatic cancer (a cancer that has already spread) of the ovaries after other treatments have failed. (mayoclinic.org)
  • This lack of progress is epitomized by the continued use of platinum/etoposide regimens as standard first-line chemotherapy for patients with both limited- and extensive-stage disease. (jnccn.org)
  • Meanwhile, though immunotherapy is being explored for limited-stage (LS)-SCLC as well, the standard treatment for such patients remains platinum/etoposide chemotherapy with concurrent radiation, plus or minus prophylactic cranial irradiation. (medpagetoday.com)
  • Chemotherapy should be administered in conjunction with radiation therapy to most patients with stage IB (high-risk) to stage IVA cervical cancer. (medscape.com)
  • This patient population "is an otherwise healthy group of women with advanced cervical cancer," Dr Cella notes. (medscape.com)
  • More research into cost, optimal dose, and different patient populations is needed for bevacizumab to "take its proper place in the advanced cervical cancer armamentarium," Dr Cella concludes. (medscape.com)
  • The median survival in the study population of 17 months considerably exceeds the median of 12 months in patients with advanced cervical cancer enrolled in previous GOG studies, and the median of 7 months or less in the general population affected by advanced cervical cancer, they all observe. (medscape.com)
  • In this study, bevacizumab combined with chemotherapy improved overall survival by 26% compared with chemotherapy alone in patients with advanced cervical cancer. (onclive.com)
  • The most common finding in patients with cervical cancer is an abnormal Papanicolaou (Pap) test result. (medscape.com)
  • Small cell lung cancer (SCLC) is an aggressive lung tumour strongly associated with cigarette smoking, with patients often presenting with metastatic disease at the time of diagnosis. (ersjournals.com)
  • however, many patients present with metastatic disease with or without any clinical symptoms. (msdmanuals.com)
  • H. Lundbeck A/S has initiated phase I clinical trials with the pharmaceutical candidate Lu AA24493 to investigate safety, tolerability and the pharmacokinetic profile of the compound in patients suffering from acute ischemic stroke. (worldpharmanews.com)
  • METHODS: In this phase 2 trial, we evaluated the antitumor activity and safety of tarlatamab, administered intravenously every 2 weeks at a dose of 10 mg or 100 mg, in patients with previously treated small-cell lung cancer. (bvsalud.org)
  • METHODS: This phase II study (ClinicalTrials.gov identifier: NCT04619004) was designed to evaluate HER3-DXd in patients with advanced EGFR-mutated NSCLC previously treated with EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy (PBC). (bvsalud.org)
  • We evaluated the reasons for non-enrolment of ovarian cancer patients in clinical trials. (nih.gov)
  • All patients with ovarian cancer not enrolled in clinical studies and treated in 2001 in the participating centres were documented retrospectively and compared with patients enrolled in clinical trials at the same institutions during the same time period. (nih.gov)
  • Two hundred and seventy-four patients with advanced ovarian cancer (FIGO stage IIB-IV) were included, of whom 139 (51%) and 135 (49%) patients were enrolled in this study and in prospective clinical trials, respectively. (nih.gov)
  • Ninety-four of 274 patients (34%) did not meet the inclusion criteria for clinical trials. (nih.gov)
  • The BTTC was created in 2003 as a network of professionals who investigate new treatments, allowing patients across the nation to participate in cutting-edge clinical trials that help health care providers more rapidly determine the benefits of various therapies. (cancer.gov)
  • Clinical trials are medical research studies conducted to understand whether promising approaches to cancer prevention, diagnosis, and treatment are safe and effective in patients. (cancer.gov)
  • Our Clinical Breast Cancer Program contributes substantial numbers of patients to institutional and national/cooperative group clinical trials with rates of accrual much higher than the national average. (umaryland.edu)
  • As in ovarian cancer, the use of intraperitoneal (IP) chemotherapy must be considered the current standard treatment option in patients with stage II-IV disease. (medscape.com)
  • The favorable recommendation was based on a review of data from two large, international, multicenter trials conducted on patients with recurrent ovarian cancer. (bio.net)
  • This retrospective study was conducted at the Institute of Hematology & Blood Diseases Hospital, for hospitalized MDS patients diagnosed (WHO 2008 classification criteria) from May 2006 to February 2020. (medscimonit.com)
  • As of April 1, 2020, in the Phase Ib study, 19 patients were treated with APG-115 in 4 alternate-day (QOD) dose cohorts (50 mg, 100 mg, 150 mg, and 200 mg) in combination with pembrolizumab. (pharmiweb.com)
  • This phase 2 clinical study determined if temozolomide administered alone or in combination with thalidomide, isotretinion, and/or celecoxib was effective in the continued treatment of newly diagnosed glioblastoma patients after radiation therapy. (cancer.gov)
  • However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs. decitabine (DAC) in adult MDS patients. (medscimonit.com)
  • In the second-line setting, ES-SCLC treatment was largely defined by the use of topotecan, though the recent introduction of lurbinectedin is providing some mixed evidence of efficacy in this space. (medpagetoday.com)
  • We assessed the efficacy and safety of HER3-DXd in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). (bvsalud.org)
  • Non-grasping en bloc MLND enables en bloc dissection of mediastinal LNs with comparable morbidity and oncological efficacy while saving troubles of excessive interference of instruments and potential damage to the target LN. (medscape.com)
  • however, the treatment of patients with metastatic or recurrent disease after platinum-based chemoradiation remains a major challenge, with limited treatment options available. (onclive.com)
  • Some patients on this medicine have developed severe, life-threatening infections. (cigna.com)
  • Patients with high topotecan AUC had an increased probability of experiencing severe neutropenia, which was greater if the patient had been pretreated with platinum-based agents. (elsevierpure.com)
  • Objective: Our objective was to describe the pharmacokinetics and pharmacodynamics of topotecan in patients. (elsevierpure.com)
  • In the PNAS paper, the researchers describe how topotecan hits its intended target -- the topoisomerase proteins that are integral for cell division, a hallmark of cancer cells. (sciencedaily.com)
  • They describe the situation this way: "Although patients living for 3.7 months longer might be another small incremental improvement, if this survival gain is considered in context of a sustained quality of life, the therapeutic effect becomes clinically meaningful. (medscape.com)
  • Compare the objective tumor response rate, progression-free survival, and disease control in patients treated with these regimens. (knowcancer.com)
  • Furthermore, these three genes predicted overall survival and recurrence‑free survival in patients with ACC from the TCGA cohort. (cancerindex.org)
  • 5 To date, platinum-based chemotherapy is the most effective therapy to treat advanced NSCLC patients, 6 with a significantly higher survival and response rate. (dovepress.com)
  • The study further demonstrated that tandem autologous HCT also benefits patients who received immunotherapy, with a significant difference in 3-year event-free survival between the 2 treatment arms ( P =.0033). (oncologynurseadvisor.com)
  • If left untreated, patients with SCLC rarely survive longer than a few months 5 , but chemotherapy dramatically prolongs survival compared to the best supportive care 6 . (ersjournals.com)
  • Among patients evaluated for antitumor activity and survival, the median follow-up was 10.6 months in the 10-mg group and 10.3 months in the 100-mg group. (bvsalud.org)
  • the estimates of overall survival at 9 months were 68% and 66% of patients, respectively. (bvsalud.org)
  • CONCLUSIONS: Tarlatamab, administered as a 10-mg dose every 2 weeks, showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. (bvsalud.org)
  • Conclusions: Patients with compromised renal function, low body weight, or poor performance status had low topotecan clearance. (elsevierpure.com)
  • However, elderly patients are more likely to have age-related liver, kidney, or heart problems, which may require an adjustment in the dose for patients receiving ranolazine. (drugs.com)
  • Patients who have undergone optimal tumor debulking should be offered IP chemotherapy. (medscape.com)
  • This phase 2 clinical study evaluated the combination of a personalized cancer vaccine made from the patient's own tumor tissue (HSPPC-96) and PD-1 inhibition (pembrolizumab) in newly diagnosed glioblastoma patients. (cancer.gov)
  • It occurs almost exclusively in immunosuppressed individuals, e.g., patients with AIDS, hematological and lymphoreticular malignancies, autoimmune rheumatological diseases, or those having undergone organ transplantation. (medscape.com)
  • When tested on mice in vivo, topotecan affected the hippocampus, striatum and cerebral cortex but not the cerebellum unless a higher dose was administered (21.6 micrograms/hour for five days). (wikipedia.org)
  • High micromolar concentrations of topotecan, which are unlikely to be achieved in plasma in human patients in vivo , were cytotoxic within 48 hr, induced DNA fragmentation, did not induce major cell cycle changes, failed to consistently alter BCL-2 or BAX protein levels but inhibited RNA synthesis and induced cleavable DNA/topoisomerase I complex formation. (aspetjournals.org)
  • These data suggest that topotecan needs to be administered in high concentrations, such as an intratumoral polymer, to limit glioma cell growth in synergy with CD95L in vivo . (aspetjournals.org)
  • Most patients are re-treated with a platinum doublet. (medscape.com)
  • This phase 1/2 clinical study evaluated the safety and efficacy of everolimus and sorafenib in patients with recurrent high-grade gliomas. (cancer.gov)
  • This phase 2 clinical study evaluated whether pazopanib is safe and effective to give in combination with topotecan, and if this pairing can control glioblastoma. (cancer.gov)
  • Nykode Therapeutics dosed the first patient in its VB-D-01 Phase I/II trial of its T cell focused next-generation SARS-CoV-2 vaccine candidate. (biospace.com)
  • Hansa Biopharma treated the first patient in its Phase III ConfideS trial of imlifidase in highly sensitized kidney transplant patients. (biospace.com)
  • Jazz Pharmaceuticals enrolled the first patient in its Phase II trial of JZP150 for post-traumatic stress disorder (PTSD). (biospace.com)
  • In thisopen-label phase I study, irinotecan was administered IV at a fixeddose of 250 mg/m2 on day 1 in combination with capecitabine at a fixeddose of 1,500 mg/m2 for days 2 to 7 and epirubicin starting at a dose of40 mg/m2 and escalating by 10 mg/m2 in cohorts of three patients forthose with metastatic adenocarcinomas. (cancernetwork.com)
  • Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. (mayo.edu)
  • BACKGROUND: Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer. (bvsalud.org)
  • Furthermore, we observed some encouraging signs of clinical activity, which warrants further evaluation in specific patient populations, including microsatellite-stable colorectal cancer [CRC] and non-small-cell lung cancer [NSCLC]. (pharmiweb.com)
  • Get answers to common questions about support and resources from Genentech for patients who have been prescribed Avastin. (avastin.com)
  • Regardless of the type of health insurance your patients have - and even if they don't have any - there may be options available to help them afford Avastin. (avastin.com)
  • Avastin Access Solutions may be able to help patients understand how to get the medicine they need. (avastin.com)
  • Avastin Access Solutions can refer patients to financial assistance options. (avastin.com)
  • No matter what type of health insurance your patients have, and even if they have none at all, there may be options available to help afford Avastin. (avastin.com)
  • Patients must have high-risk neuroblastoma that has not yet been treated with chemotherapy. (mskcc.org)
  • Topotecan is often given in combination with paclitaxel as first line treatment for extensive-stage small-cell lung cancer. (wikipedia.org)
  • UNC postdoctoral fellow Angela Mabb, PhD, used several biochemical, electrophysiological, and imaging techniques to study how cortical neurons of mice react to topotecan. (sciencedaily.com)
  • Topotecan belongs to the group of medicines called antineoplastics. (mayoclinic.org)
  • This drug has been administered to cancer patients. (wikipedia.org)
  • Hydroxyurea (hydroxycarbamate, Hydrea) is a chemo drug that has helped some patients with CMML live longer. (cancer.org)
  • Some patients have stayed on this drug for years without problems. (cancer.org)
  • Scientists discovered how the chemo drug topotecan affects individual neurons to potentially cause "chemo fog. (sciencedaily.com)
  • The research, published in the Proceedings of the National Academy of Sciences , shows how the common chemotherapy drug topotecan can drastically suppress the expression of Topoisomerase-1, a gene that triggers the creation of proteins essential for normal brain function. (sciencedaily.com)
  • The UMGCCC clinical breast program continues to work in the area of clinical drug development with the focus on hormone resistance, role of microtentacles in breast cancer metastasis, the significance of brown adipose tissue in pathogenesis and progression of breast cancer, the GP-88 circulating marker and its significance in patients with breast cancer and in screening for breast cancer. (umaryland.edu)
  • Jodrell DI, Reyno L, Sridhara R, Eisenberger M, Tkaczuk K , Zuhowski E, Sinibaldi V, Novak M, and Egorin M. Suramin: Development of a Population Pharmacokinetic Model and Its Use With Intermittent Short Infusions to Control Plasma Drug Concentration in Patients with Prostate Cancer. (umaryland.edu)
  • He mentioned another drug (can't remember the name of it) is an oral chemo that we can try if topotecan and germzar fail. (cancer.org)
  • An objective response occurred in 40% (97.5% confidence interval [CI], 29 to 52) of the patients in the 10-mg group and in 32% (97.5% CI, 21 to 44) of those in the 100-mg group. (bvsalud.org)
  • Among patients with an objective response, the duration of response was at least 6 months in 59% (40 of 68 patients). (bvsalud.org)
  • Objective responses at the time of data cutoff were ongoing in 22 of 40 patients (55%) in the 10-mg group and in 16 of 28 patients (57%) in the 100-mg group. (bvsalud.org)
  • After GlaxoSmithKline received final FDA approval for topotecan on October 15, 2007, it became the first topoisomerase I inhibitor for oral use. (wikipedia.org)
  • Dosimetric patterns of failure in the era of novel chemoradiotherapy in newly-diagnosed glioblastoma patients. (mayo.edu)
  • These patients have been re-treated with platinum-based chemotherapy. (medscape.com)
  • It is very good to know that at UNC we have a big effort to study patient-reported outcomes during therapy so that we can balance care for the whole person. (sciencedaily.com)
  • The subgroup of patients with previous osimertinib and PBC had similar outcomes. (bvsalud.org)